Literature DB >> 11807776

CTLA-4 regulates cell cycle progression during a primary immune response.

Rebecca J Greenwald1, Mariette A Oosterwegel, Diane van der Woude, Anup Kubal, Didier A Mandelbrot, Vassiliki A Boussiotis, Arlene H Sharpe.   

Abstract

Engagement of CTLA-4 is critical for inhibiting T cell immune responses. Recent studies have shown that CTLA-4 plays a key role in regulating peripheral T cell tolerance. It has been suggested that one mechanism by which CTLA-4 performs this function is by regulating cell cycle progression. Here, we investigate in depth the role of CTLA-4 in regulating cell cycle progression in naive T cells by comparing the immune responses in the absence or presence of CTLA-4. In the absence of CLTA-4, T cells exhibit marked increases in T cell proliferation, IL-2 mRNA and protein secretion, and cells cycling in the S and G2-M phase. Analyses of cyclins, cyclin-dependent kinases, and cell cycle inhibitors involved in the transition from the G1 to S phase reveal that cell cycle progression is prolonged in the absence of CTLA-4. This is due to the early exit from the G1 phase, entry into the S phase, and prolonged S phase period. Re-expression of the cell cycle inhibitor p27(kip1) is delayed in the absence of CTLA-4. These studies demonstrate that the B7 : CTLA-4 pathway exerts its major effects on T cell immune responses via regulation of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807776     DOI: 10.1002/1521-4141(200202)32:2<366::AID-IMMU366>3.0.CO;2-5

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  40 in total

Review 1.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

2.  CTLA-4 polymorphisms and susceptibility to Behcet's disease: a meta-analysis.

Authors:  Young Ho Lee; Gwan Gyu Song
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

Review 3.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok; James P Allison
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

Review 4.  The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review.

Authors:  Si Chen; Yuan Li; Chuiwen Deng; Jing Li; Xiaoting Wen; Ziyan Wu; Chaojun Hu; Shulan Zhang; Ping Li; Xuan Zhang; Fengchun Zhang; Yongzhe Li
Journal:  Rheumatol Int       Date:  2015-08-01       Impact factor: 2.631

Review 5.  Modification of accessory molecule signaling.

Authors:  Mary K Crow
Journal:  Springer Semin Immunopathol       Date:  2006-05-16

6.  Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis.

Authors:  Je-Min Choi; Seung-Hyung Kim; Jae-Hoon Shin; Thomas Gibson; Byoung-Seok Yoon; Dong-Ho Lee; Seung-Kyou Lee; Alfred L M Bothwell; Jong-Soon Lim; Sang-Kyou Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-09       Impact factor: 11.205

7.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

Authors:  Peter Attia; Giao Q Phan; Ajay V Maker; Michael R Robinson; Martha M Quezado; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Nicholas P Restifo; Leah R Haworth; Catherine Levy; Sharon A Mavroukakis; Geoff Nichol; Michael J Yellin; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

8.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.

Authors:  Josef Kurtz; Forum Raval; Casey Vallot; Jayden Der; Megan Sykes
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

9.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

10.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

Authors:  Karl S Peggs; Sergio A Quezada; Cynthia A Chambers; Alan J Korman; James P Allison
Journal:  J Exp Med       Date:  2009-07-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.